Datopotamab Deruxtecan Improves Survival in Triple-Negative Breast Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on April 22, 2026.

via HealthDay

WEDNESDAY, April 22, 2026 -- For patients with previously untreated, locally recurrent inoperable or metastatic, advanced triple-negative breast cancer (TNBC), first-line datopotamab deruxtecan (Dato-DXd) is associated with improvements in progression-free survival (PFS) and overall survival (OS), according to a study published online April 3 in the Annals of Oncology.

Rebecca Dent, M.D., from the National Cancer Centre Singapore, and colleagues conducted a randomized, phase 3 trial involving patients with previously untreated, locally recurrent inoperable or metastatic TNBC for whom immunotherapy was not an option. Participants were randomly assigned to receive Dato-DXd (6 mg/kg intravenously every three weeks) or the investigator's choice of chemotherapy (323 and 321 participants, respectively). PFS and OS were dual primary end points.

The researchers found that the median PFS was 10.8 months with Dato-DXd and 5.6 months with chemotherapy (hazard ratio [HR], 0.57). The corresponding median OS was 23.7 and 18.7 months, respectively (HR, 0.79). Overall, 33 percent of patients who received Dato-DXd and 29 percent who received chemotherapy had treatment-related adverse events (TRAEs) of grade ≥3; TRAEs led to treatment discontinuation in 4 and 7 percent, respectively. No treatment-related deaths occurred.

"First-line Dato-DXd demonstrated clinically meaningful and significant improvements in PFS and OS for these TNBC patients," Dent said in a statement.

Several authors report ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-04-23 02:08

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords